These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 19020383)

  • 21. Insulin Resistance and the cardiometabolic syndrome in HIV infection.
    Bevilacqua M; Dominguez LJ; Barbagallo M
    J Cardiometab Syndr; 2009; 4(1):40-3. PubMed ID: 19245515
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum leptin concentrations and fat redistribution in HIV-1-infected children on highly active antiretroviral therapy.
    Dzwonek AB; Novelli V; Schwenk A
    HIV Med; 2007 Oct; 8(7):433-8. PubMed ID: 17760735
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metabolic consequences and therapeutic options in highly active antiretroviral therapy in human immunodeficiency virus-1 infection.
    Samaras K
    J Antimicrob Chemother; 2008 Feb; 61(2):238-45. PubMed ID: 18070830
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lipodystrophy severity does not contribute to HAART nonadherence.
    Collins EJ; Burgoyne RW; Wagner CA; Abbey SE; Halman MH; Nur ML; Walmsley SL
    AIDS Behav; 2006 May; 10(3):273-7. PubMed ID: 16421650
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection.
    Powles T; Robinson D; Stebbing J; Shamash J; Nelson M; Gazzard B; Mandelia S; Møller H; Bower M
    J Clin Oncol; 2009 Feb; 27(6):884-90. PubMed ID: 19114688
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lipodystrophy in HIV 1-infected patients: lessons for obesity research.
    Villarroya F; Domingo P; Giralt M
    Int J Obes (Lond); 2007 Dec; 31(12):1763-76. PubMed ID: 17653062
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Growth hormone deficiency in HIV-infected children following successful treatment with highly active antiretroviral therapy.
    Watson DC; Counts DR
    J Pediatr; 2004 Oct; 145(4):549-51. PubMed ID: 15480383
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vascular injury, hypertension and coronary artery disease in human immunodeficiency virus infection.
    Barbaro G
    Clin Ter; 2008; 159(1):51-5. PubMed ID: 18399263
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Toxicogenetics of antiretroviral therapy: genetic factors that contribute to metabolic complications.
    Tarr PE; Telenti A
    Antivir Ther; 2007; 12(7):999-1013. PubMed ID: 18018758
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Lipodystrophy in HIV infected children].
    Popielska J
    Pol Merkur Lekarski; 2008 May; 24(143):408-13. PubMed ID: 18634383
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HIV lipodystrophy etiology and pathogenesis. Body composition and metabolic alterations: etiology and pathogenesis.
    Kotler DP
    AIDS Read; 2003 Apr; 13(4 Suppl):S5-9. PubMed ID: 12762287
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cerebrovascular ischemic events in HIV-1-infected patients receiving highly active antiretroviral therapy: incidence and risk factors.
    Corral I; Quereda C; Moreno A; Pérez-Elías MJ; Dronda F; Casado JL; Muriel A; Masjuán J; Alonso-de-Leciñana M; Moreno S
    Cerebrovasc Dis; 2009; 27(6):559-63. PubMed ID: 19390181
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rheumatic manifestations associated with HIV in the highly active antiretroviral therapy era.
    Nguyen BY; Reveille JD
    Curr Opin Rheumatol; 2009 Jul; 21(4):404-10. PubMed ID: 19444116
    [TBL] [Abstract][Full Text] [Related]  

  • 34. GH/GHRH axis in HIV lipodystrophy.
    Stanley TL; Grinspoon SK
    Pituitary; 2009; 12(2):143-52. PubMed ID: 18270841
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HIV disease and an atherosclerotic ascending aortic aneurysm.
    Mirza H; Patel P; Suresh K; Krukenkamp I; Lawson WE
    Rev Cardiovasc Med; 2004; 5(3):176-81. PubMed ID: 15346102
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Growth hormone and HIV infection: contribution to disease manifestations and clinical implications.
    Falutz J
    Best Pract Res Clin Endocrinol Metab; 2011 Jun; 25(3):517-29. PubMed ID: 21663844
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HIV-associated facial lipoatrophy--review of current therapy options.
    Bechara FG; Sand M; Potthoff A; Altmeyer P; Brockmeyer NH;
    Eur J Med Res; 2008 Mar; 13(3):93-9. PubMed ID: 18499554
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HIV in older adults.
    Simone MJ; Appelbaum J
    Geriatrics; 2008 Dec; 63(12):6-12. PubMed ID: 19061274
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of facial lipoatrophy in HIV-infected patients.
    Prescrire Int; 2008 Aug; 17(96):170. PubMed ID: 19492497
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HIV and HIV treatment: effects on fats, glucose and lipids.
    Gkrania-Klotsas E; Klotsas AE
    Br Med Bull; 2007; 84():49-68. PubMed ID: 17981955
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.